TY - JOUR
T1 - Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals
AU - Winkler, Thomas W
AU - Rossing, Peter
AU - Ahluwalia, Tarunveer S
AU - LifeLines Cohort study
N1 - © 2022. The Author(s).
PY - 2022/6/13
Y1 - 2022/6/13
N2 - Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (n
DM = 178,691, n
noDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.
AB - Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (n
DM = 178,691, n
noDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.
KW - Creatinine
KW - Diabetes Mellitus
KW - Diabetic Nephropathies/genetics
KW - Genome-Wide Association Study
KW - Glomerular Filtration Rate/genetics
KW - Humans
KW - Kidney
UR - http://www.scopus.com/inward/record.url?scp=85131867525&partnerID=8YFLogxK
U2 - 10.1038/s42003-022-03448-z
DO - 10.1038/s42003-022-03448-z
M3 - Journal article
C2 - 35697829
SN - 2399-3642
VL - 5
SP - 580
JO - Communications biology
JF - Communications biology
IS - 1
M1 - 580
ER -